Trials / Completed
CompletedNCT02600416
The CIRE Study (CItrate REcirculation Study)
Effects of AV Port Reversal in Citrate CVVH - The CIRE Study (CItrate REcirculation Study)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Ziekenhuis Oost-Limburg · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to determine the effects of AV port reversal (AVPR) on recirculation, clearance, post-filter ionized calcium and subsequently citrate dosing.
Detailed description
Rationale: AV port reversal (AVPR) has been demonstrated to increase recirculation in venous catheters used in ICU for CVVH. The effects of this frequently used manoeuvre have not been described in the setting of CVVH using regional citrate anticoagulation. Objective: The aim of this study is to determine the effects of AVPR on recirculation, clearance, post-filter ionized calcium and subsequently citrate dosing. Study design and methods: Open trial studying the effect of AVPR in patients undergoing citrate CVVH. After measurement in standard catheter configuration, AVPR is performed after which effects on catheter recirculation, clearance, citrate dosing and post-filter ionized calcium (iCa) are monitored. Sample sites: Arterial line, arterial (pre-filter) port, postfilter port (after postdilution and calcium compensation), effluent sample. All flow rates to be noted. Study population: Twelve patients admitted to intensive care, requiring continuous renal replacement therapy (CRRT) for AKI. Patients are preferably anuric and have achieved good metabolic control under CVVH before inclusion in the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | AV port reversal | Reversal of the AV port at 1h Reversal of the AV port to start position at 7h |
Timeline
- Start date
- 2015-12-01
- Primary completion
- 2017-09-01
- Completion
- 2017-09-01
- First posted
- 2015-11-09
- Last updated
- 2018-03-30
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT02600416. Inclusion in this directory is not an endorsement.